Immunotherapy and Hodgkin Lymphoma Survival

Headshots of Jenna Rogers (Upper Left), Zachary Ward (Lower Left), and Jennifer Yeh Against Art Background

PhD candidate Jenna Rogers, CHDS faculty Jennifer Yeh and Zachary Ward, and colleagues developed a decision-analytic microsimulation model to project lifetime outcomes for children and adolescents with advanced-stage Hodgkin lymphoma treated with newer regimens that include brentuximab vedotin or nivolumab. The article was published in the Journal of the National Cancer Institute.

Children treated for Hodgkin lymphoma in earlier decades have experienced serious health problems later in life, and data on late toxicity after newer immunotherapy agents are not yet available. Using the Cancer Outcomes Microsimulation: Pediatric and Adolescent SurvivorShip (COMPASS) model, the researchers simulated outcomes for regimens tested in two clinical trials and compared them with survivors treated in the 1990s and the general population.

At age 50, projected overall survival was 92.3%-93.3% with the immunotherapy-based regimens, compared with 85.8% for historically treated survivors and 95.8% in the general population. Projected life expectancy was 72.3 years after brentuximab vedotin-based therapy and 73.5 years after nivolumab-based therapy, compared with 66.5 years for survivors treated in the 1990s. Sensitivity analyses suggested that projected life expectancy with the newer regimens would remain longer than for 1990s-era survivors unless immunotherapy-related late mortality exceeded approximately 8%. The authors noted that survivors will continue to need lifelong, risk-based follow-up, along with ways to track long-term outcomes after contemporary regimens.

Learn more: Read the full publication, Immunotherapy-Based Therapies in Pediatric Hodgkin Lymphoma: Potential to Narrow the Gap in Long-Term Survival

Related news: Accelerated Aging in Childhood Cancer Survivors
Related news: Colorectal Screening in Childhood Cancer Survivors